Clinician's Roundtable

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Mallik Greene, PhD Guest: Jordan Karlitz, MD A study published in the Journal of the National Comprehensive Cancer Network examined follow-up colonoscopy rates after positive stool-based colorectal cancer screening tests, finding notably higher and faster completion rates with multi-target stool DNA testing compared to fecal immunochemical testing. These findings highlight the critical role of patient navigation in closing follow-up gaps and reducing disparities across racial and ethnic groups. Joining Dr. Peter Buch to discuss their research and its implications for everyday practice are Dr. Mallik Greene and Dr. Jordan Karlitz. Dr. Greene is a health economics and outcome research expert at Abbott Cancer Diagnostics, and Dr. Karlitz is a volunteer gastroenterology professor at the University of Colorado School of Medicine and a Senior Medical Officer at Abbott Cancer Diagnostics.

Host: Brian P. McDonough, MD, FAAFP Guest: David A. Lieberman, MD Long-term effectiveness of colorectal cancer (CRC) screening depends on more than the performance of an individual test; it requires sustained adherence to recommended screening intervals and timely follow-up after abnormal results. But real-world data shows that many patients fall off track over time. Learn more about how we can improve adherence, reduce disparities, and strengthen continuity across the screening pathway as Dr. Brian McDonough sits down with Dr. David Lieberman, Professor Emeritus in the Department of Medicine and former Chief of the Division of Gastroenterology and Hepatology at Oregon Health & Science University in Portland.

Host: Shelina Ramnarine, PhD Guest: Samuel Ubanyionwu, PharmD, EMBA Accurate IV medication delivery depends on more than proper pump programming alone. It requires a comprehensive understanding of smart pump drug libraries, dose error reduction software (DERS), infusion mechanics, and system-level safety procedures. To explore how these elements work together to support IV medication accuracy, patient safety, and clinical decision-making, Dr. Shelina Ramnarine speaks with Dr. Samuel Ubanyionwu, Medication Management Informaticist in Pharmacy Services and an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine.

Guest: Sayna Norouzi, MD Because patients with IgA nephropathy (IgAN) often have few symptoms early in the disease course, communicating the importance of treatment and its impacts on long-term outcomes can be challenging. Join Dr. Sayna Norouzi as she discusses practical communication techniques for explaining prognosis, setting expectations around therapy, and partnering with patients to support informed treatment decisions and long-term kidney health. Dr. Norouzi is an Associate Professor of Medicine and Clinical Nephrologist at Loma Linda University Medical Center in California. She's also the Founder and Director of the Glomerular Diseases Clinic at Loma Linda and Director of the GlomCon Glomerular Diseases Fellowship Program.

Guest: Anjay Rastogi, MD, PhD Managing IgA nephropathy (IgAN) is becoming increasingly complex. In this episode, Dr. Anjay Rastogi explains why an expert opinion—not simply a second opinion—can help clinicians confirm diagnoses, optimize treatment decisions, and connect appropriate patients with specialized care and emerging therapeutic opportunities. Dr. Rastogi is a Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA. He's also the Director of the UCLA CORE Kidney Health Program.

Guest: Anjay Rastogi, MD, PhD Closer collaboration between nephrologists and pathologists is essential for optimizing the diagnosis and management of IgA nephropathy (IgAN). Hear from Dr. Anjay Rastogi as he highlights how pathology insights, clinical context, and ongoing communication can improve interpretation of kidney biopsy findings and support more informed treatment decisions. He's a Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, as well as the Director of the UCLA CORE Kidney Health Program.

Host: Alexandria May, PharmD, BCPS Guest: David E. Griffith, MD Even as our understanding of nontuberculous mycobacterial (NTM) lung disease advances, major gaps remain, from defining meaningful treatment success to overcoming innate drug resistance. In this conversation with Dr. Alexandria May, Dr. David Griffith shares his perspective on how recent evidence is shaping treatment decisions for these patients and explains why significant unmet needs persist. Dr. Griffith is a Professor of Medicine in the Division of Mycobacterial and Respiratory Infections within the Department of Medicine at National Jewish Health in Denver.

Host: Brian P. McDonough, MD, FAAFP Guest: Doreen Addrizzo-Harris, MD The biggest challenge in diagnosing nontuberculous mycobacterial (NTM) lung disease isn't confirmation; it's thinking to look for NTM in the first place. In this conversation with Dr. Brian McDonough, Dr. Doreen Addrizzo-Harris examines the subtle clinical and radiographic features that can help identify NTM earlier, discusses best practices for obtaining diagnostic cultures, and reviews how guideline-based criteria can help distinguish active disease from colonization. Dr. Addrizzo-Harris is the Fiona and Stanley Druckenmiller Professor of Pulmonary, Critical Care, and Sleep Medicine at NYU Grossman School of Medicine, as well as the Director of the Bronchiectasis and NTM Program at NYU Langone Health.

What do large registry data reveal about outcomes after intraocular foreign body removal, and how should those findings shape surgical planning and patient counseling? In this episode of New Retina Radio Journal Club with VBS, Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, on a 2025 IRIS Registry analysis of nearly 4,800 eyes. The group reviews the delayed timeline of visual recovery, the risk of late complications, and practical guidance on staging surgical intervention and setting realistic expectations in complex trauma cases.

Host: Maria Berrocal Guest: Audina Berrocal, MD Does socioeconomic status influence outcomes in proliferative sickle retinopathy? In this episode of Clinical Minute: Retina, host Maria Berrocal, MD, speaks with Audina "Nina" Berrocal, MD, of Bascom Palmer Eye Institute, who published a retrospective review of more than 100 patients with proliferative sickle retinopathy. They explore whether the integrated care model at Bascom Palmer may account for results that don't translate to other parts of the country. The conversation also touches on newborn screening programs in Florida and the importance of sickle cell centers in high-incidence communities.

Guest: Jason Goldman, MD Scientific uncertainty is inevitable, but how we communicate it matters. Dr. Jason Goldman, President of the American College of Physicians and liaison to the CDC Advisory Committee on Immunization Practices, shares strategies for discussing the unknown with patients transparently and effectively.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kenneth Olivier, MD, MPH Guest: Shelby MacRae, MD In patients with nontuberculous mycobacterial (NTM) lung disease, treatment decisions rarely follow a one-size-fits-all approach. In this expert-led discussion, Dr. Kenneth Olivier and Dr. Shelby MacRae join Dr. Charles Turck to explore how disease characteristics, patient priorities, and evolving clinical factors can inform individualized treatment strategies across the NTM care continuum. Dr. Olivier is the Michael E. Hatcher Distinguished Professor of Medicine, Microbiology, and Immunology at the University of North Carolina School of Medicine, where he also serves as Research Director of the Bronchiectasis and NTM Care and Research Center. Dr. MacRae is an Assistant Professor of Pulmonary and Critical Care Medicine and Director of the Environmental Lung Disease, Bronchiectasis, and NTM Program at Louisiana State University Health Sciences Center in New Orleans.

Guest: Christopher Cann, MD Colorectal cancer is increasingly affecting younger adults, highlighting important gaps in current screening practices. Given this alarming trend, Dr. Christopher Cann discusses how rising incidence in patients under 50 challenges traditional screening thresholds and underscores the need for earlier risk assessment. He emphasizes the importance of family history, identifying high-risk individuals who may benefit from earlier screening, and maintaining a low threshold to evaluate persistent symptoms. Dr. Cann is an Assistant Professor in the Department of Hematology Oncology at Fox Chase Cancer Center in Philadelphia, where he's also the Director of the Young Adult Cancer Program.

Guest: Christopher Cann, MD Patient navigators play an increasingly vital role in improving colorectal cancer screening rates and closing gaps in preventive care. Beyond care coordination, they serve as key educators by identifying eligible patients, addressing barriers, and facilitating referrals for screening colonoscopy and other modalities. Learn more about how integrating patient navigation can enhance adherence and ultimately improve patient outcomes with Dr. Christopher Cann, Assistant Professor in the Department of Hematology Oncology and Director of the Young Adult Cancer Program at Fox Chase Cancer Center in Philadelphia.

Host: Gates B. Colbert, MD Guest: Sarina Schrager, MD Guest: Lashika Yogendran, MD Shared decision-making plays a critical role in improving colorectal cancer screening uptake by helping patients navigate emotional, logistical, and personal barriers to care. Joining Dr. Gates Colbert to discuss how individualized, patient-centered conversations can support screening decisions and improve completion rates are Dr. Sarina Schrager and Dr. Lashika Yogendran. Dr. Schrager is a family medicine physician at the University of Wisconsin School of Medicine and Public Health, where she focuses on preventative care, women's care, and patient-centered decision-making. Dr. Yogendran is a family medicine physician at UW Health and an Assistant Professor at the University of Wisconsin School of Medicine and Public Health, Department of Family Medicine and Community Health.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH Despite strong recommendations for colorectal cancer screening, many eligible patients are still unscreened because of access and convenience issues. Emerging blood-based screening tests may help expand participation, but important questions remain about their ability to detect advanced precursor lesions and how they compare with established screening approaches. Joining Dr. Peter Buch to discuss the evolving role of blood-based colorectal cancer screening and what clinicians should know about these new testing strategies is Dr. Aasma Shaukat. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Director of Outcomes Research in Gastroenterology.

Guest: Natalia Usoltseva MD, FACP, MHA Colorectal cancer screening (CRC) is one of the most powerful preventive tools in primary care, but disconnected workflows can make it difficult for both clinicians and patients to stay on track. Hear Dr. Natalia Usoltseva, a primary care provider at University of Washington Medicine, talk about how integrating Epic Aura in her organization helped create a more seamless, coordinated approach to FIT-DNA screening, follow-up, and shared decision-making.

Guest: Natalia Usoltseva MD, FACP, MHA Colorectal cancer (CRC) screening is most effective when it fits seamlessly into busy primary care workflows while still keeping patients engaged in the process. Join Dr. Natalia Usoltseva as she discusses practical ways to improve screening, from simplifying shared decision-making conversations and automating follow-up processes to ensuring patients receive the individualized support they need to stay on track with preventive care. Dr. Usoltseva is a primary care provider at University of Washington Medicine.

Guest: Natalia Usoltseva MD, FACP, MHA Shared decision-making can be difficult to incorporate into already time-constrained primary care visits, especially when discussing colorectal cancer screening (CRC) options with patients. Join Dr. Natalia Usoltseva, a primary care provider at University of Washington Medicine, to hear how her practice implemented standardized decision-making tools to create more efficient, patient-centered conversations and improve colorectal cancer screening adherence.

Guest: Christopher Cann, MD Delayed colorectal cancer screening can significantly impact not only clinical outcomes, but also patients’ long-term quality of life. Tune in to hear Dr. Christopher Cann share his insights on these lasting consequences, including the need for more extensive surgery and systemic therapies, the burden of chemotherapy-related toxicities, and the broader implications for patients like limitations on daily activities, work, and fertility. Dr. Cann is an Assistant Professor in the Department of Hematology Oncology at Fox Chase Cancer Center in Philadelphia, where he's also the Director of the Young Adult Cancer Program.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Christopher Cann, MD Timely colorectal cancer screening can mean the difference between prevention, cure, and advanced disease. Even delays as short as a year are associated with significantly increased risks of advanced cancer and mortality. Given this risk, Dr. Peter Buch speaks with Dr. Christopher Cann about the varying sensitives of available screening modalities, key patient barriers to adherence, and practical strategies to improve screening uptake. Dr. Cann is an Assistant Professor in the Department of Hematology Oncology at Fox Chase Cancer Center in Philadelphia, where he's also the Director of the Young Adult Cancer Program.

Guest: Mallik Greene, PhD A recent retrospective study evaluated how combining shared decision making and EHR-enabled workflow optimization impacted colorectal cancer (CRC) screening adherence among patients aged 45 and older. Learn more as Dr. Mallik Greene dives into the details and explains how this approach could improve patient engagement. Dr. Greene's background includes a PhD and a Postdoctoral Fellowship in Health Economics and Outcomes Research, as well as a Doctorate in Business Administration.

Guest: Aasma Shaukat, MD, MPH As fecal immunochemical testing (FIT) becomes more common in colorectal cancer screening, questions remain about post-FIT follow-up, especially when colonoscopies yield negative results. To explore this further, a recent review looked at the risk of colorectal cancer postcolonoscopy and analyzed the most common reasons it may occur. Hear Dr. Aasma Shaukat, a coauthor of the review, discuss the rationale behind it and its findings, which highlighted the importance of colonoscopy quality. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine and a Professor in the Department of Population Health at NYU Grossman School of Medicine. She also serves as the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU Langone Health.

Guest: Aasma Shaukat, MD, MPH Despite available options like stool-based testing and colonoscopy, colorectal cancer screening rates remain low. Blood-based testing, however, has the potential to improve adherence by offering a convenient alternative. Join Dr. Aasma Shaukat as she discusses the clinical performance of blood-based testing, its limitations, and its role in real-world settings. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine and a Professor in the Department of Population Health at NYU Grossman School of Medicine. She also serves as the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU Langone Health.

Host: Ashley Baker, MSN, PMHNP Guest: Heather Allen, PhD Guest: Ran Li, PhD Fourier Transform Infrared (FTIR) spectroscopy is emerging as a powerful tool for distinguishing cancerous from noncancerous tissue during colorectal cancer surgery. In a recent study, Drs. Heather Allen and Ran Li leveraged a broad dataset from multiple sources to identify and validate biomarkers—most notably B1—that demonstrated strong correlation with standard pathology. Hear Drs. Allen and Li walk through their study and the implications of its findings with Ashley Baker. Dr. Allen is a Full Professor in the Department of Chemistry and Biochemistry as well as the Department of Pathology at Ohio State University in Columbus, and Dr. Li is a researcher who completed a PhD in Analytical Chemistry at The Ohio State University in 2015.

Guest: Theodore Levin, MD In light of guidelines for the starting age of colorectal cancer screening shifting, a recent study explored how screening outcomes compare in adults age 45 to 49 and adults over 50. Across metrics like initiation, adherence, adenoma detection, and colonoscopy yield, the evidence shows support for earlier screening. Tune in to hear Dr. Theodore Levin, Professor of Health System Science at the Kaiser Permanente School of Medicine, the Associate Director at the Kaiser Permanente Northern California Division of Research, and the Clinical Lead for Colorectal Cancer Screening for the Permanente Medical Group, break down the research.

Guest: Theodore Levin, MD For younger adults needing to get screened for colorectal cancer, fecal immunochemical testing (FIT) may help with initiation and adherence because of its speed, ease, and noninvasiveness. Hear Dr. Theodore Levin discuss FIT and its potential benefits, particularly in younger adults. Dr. Levin is a Professor of Health System Science at the Kaiser Permanente School of Medicine, the Associate Director at the Kaiser Permanente Northern California Division of Research, and the Clinical Lead for Colorectal Cancer Screening for the Permanente Medical Group.

Host: Ryan Quigley Guest: Mallik Greene, PhD A recent study showed that tailored Spanish-language navigation paired with the multi-target stool DNA (mt-sDNA) test can significantly improve colorectal cancer re-screening adherence among Spanish-speaking patients. Hear Ryan Quigley speak with Dr. Mallik Greene, a coauthor of the study, about how these findings could shape the future of colorectal cancer screening in Spanish-speaking populations. Dr. Greene’s educational background includes a Bachelor’s degree in Pharmacy, a PhD and a Postdoctoral Fellowship in Health Economics and Outcomes Research, and a Doctorate in Business Administration.

Guest: Pedro Nascimento de Lima, PhD Conflicting colorectal cancer screening (CRC) guidelines have sometimes led to confusion over optimal starting ages and strategies. Join Dr. Pedro Nascimento de Lima as he walks through a comprehensive modeling study that tested 26 different strategies over 4,000 scenarios to test how and when it is most effective to screen. Dr. Nascimento de Lima is an Engineer at RAND, a Professor at the RAND School of Public Policy, and an investigator with the colorectal modeling group of the Cancer Intervention and Surveillance Modeling Network.

Guest: Reid Ness, MD According to the NCCN Guidelines for Colorectal Cancer Screening, there is mixed evidence around the impact of vitamin D, calcium, folate, and aspirin on colorectal cancer risk. Join Dr. Reid Ness as he discusses considerations for recommending these supplements based on patient-specific factors. Dr. Ness is an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, Tennessee, faculty with the Vanderbilt Ingram Cancer Center, and the Chairman of the committee that developed the colorectal cancer screening guidelines.

Guest: Reid Ness, MD The NCCN Guidelines for Colorectal Cancer Screening recently provided updates for patients at average and increased risk—most notably, lowering the recommended starting age from 50 to 45. Hear Dr. Reid Ness walk through the updates in depth, providing insight on screening protocols for different patient populations. Dr. Ness is an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, Tennessee, faculty with the Vanderbilt Ingram Cancer Center, and the Chairman of the committee that developed the colorectal cancer screening guidelines.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gloria Coronado, PhD Colorectal cancer screening saw significant disruptions during the COVID-19 pandemic, a challenge that has also been reflected during natural disasters such as hurricanes and wildfires. Dr. Gloria Coronado joins Dr. Charles Turck to discuss how these kinds of crises impact screening rates and how a focus on community-based care, telehealth and home-based testing, and targeted efforts for underserved populations can strengthen resilience and ensure continuity of care during future disasters. Dr. Coronado is a Professor of Epidemiology and the Associate Director of Population Science for the University of Arizona Cancer Center in Tucson.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gloria Coronado, PhD Guest: Amanda Petrik, PhD The SMARTER CRC trial evaluated mailed fecal immunochemical (FIT) outreach and patient navigation strategies across rural clinics, analyzing how implementation factors like clinic-sent letters, consistent FIT usage, and active participation in health plan meetings impacted screening outcomes. Two authors of the study, Dr. Gloria Coronado and Dr. Amanda Petrik, join Dr. Charles Turck to discuss their findings and how these results may help guide effective, scalable screening interventions for underserved populations. Dr. Coronado is a Professor of Epidemiology and the Associate Director of Population Science for the University of Arizona Cancer Center in Tucson, and Dr. Petrik is an investigator at the Kaiser Permanente Center for Health Research in Portland, Oregon, where she focuses on cancer screening and prevention in real-world settings.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jane McElroy, PhD Guest: Jean Wang, MD, PhD Guest: Nuha Wareg, MPH, MBBS Colorectal cancer screening remains underutilized across several underserved populations, including racial minorities and rural communities. That’s why Dr. Charles Turck speaks with Drs. Jane McElroy, Jean Wang, and Nuha Wareg to learn about practical, evidence-based strategies we can implement to improve screening uptake, reduce disparities, and promote high-quality, equitable care. Dr. McElroy is a Professor in the University of Missouri’s Family and Community Medicine Department and the Co-Director of its Rural Health Research Center, Dr. Wang is a Professor of Medicine and Surgery in the Division of Gastroenterology at Washington University School of Medicine, and Dr. Wareg serves as a Practice Facilitator for the Missouri Partnership to Improve Colorectal Cancer Screening program at the University of Missouri.

Host: Brian P. McDonough, MD, FAAFP Guest: Carolyn Rutter, PhD Guest: Gloria Coronado, PhD Colorectal cancer screening strategies have significantly evolved in recent years, with noninvasive options like stool and blood-based tests explored for their potential to boost adherence. Drs. Gloria Coronado and Carolyn Rutter join Dr. Brian McDonough to evaluate how these methods compare to traditional colonoscopy in terms of cost-effectiveness, accessibility, and their ability to overcome screening barriers, particularly in underserved populations. Dr. Coronado is a Professor of Epidemiology and the Associate Director of Population Science for the University of Arizona Cancer Center, and Dr. Rutter is a Professor in the Biostatistics Program and Principal Investigator for a Cancer Intervention and Surveillance Modeling Network team at Fred Hutchinson Cancer Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Dougherty, MD Rural populations face unique challenges in accessing colorectal cancer screening, leaving many patients in these communities unscreened. However, mailed fecal immunochemical testing (FIT) may help address these barriers and improve adherence. Joining Dr. Peter Buch to discuss the benefits and limitations associated with FIT and its potential impact on the colorectal cancer screening landscape is Dr. Michael Dougherty. Dr. Dougherty is an Adjunct Assistant Professor in the Division of Gastroenterology and Hepatology at the University of North Carolina School of Medicine.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: A. Mark Fendrick, MD Colorectal cancer screening saves lives—but how do common methods like colonoscopy and non-invasive screening methods compare in their environmental effects? With the healthcare sector being responsible for over four percent of the global carbon footprint, researchers are looking into more environmentally friendly options that can still provide optimal outcomes for patients. Dr. Peter Buch sits down with Dr. Mark Fendrick to examine the carbon footprint of available colorectal cancer screening strategies and explore how a shift to noninvasive options could offer promising clinical and environmental impacts. Dr. Fendrick is a Professor of Internal Medicine and Health Management and Policy at the University of Michigan.

Host: John Russell, MD Guest: Richard Wender, MD From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations. For more information and to review the new guidelines, go to cancer.org

Guest: Jemel Bingham, MD Integrating colorectal cancer screening into OB/GYN care expands preventive services and supports comprehensive patient health. Tune in to hear Dr. Jemel Bingham discuss practical workflow strategies, EHR integration, and patient-centered approaches to streamline screening and follow-up care. Dr. Bingham is a board-certified OB/GYN at Hartford Hospital and other affiliated medical groups in Connecticut.

Guest: Harish Gagneja, MD Colorectal cancer often develops without symptoms, making proactive screening essential for early detection and prevention. Tune in to hear Dr. Harish K. Gagneja, a board-certified gastroenterologist in Austin, Texas, explain how patient risk, test selection, and follow-up care influence smart and effective screening strategies.

Guest: Harish Gagneja, MD Colorectal cancer is highly preventable, but many eligible patients remain unscreened due to common barriers and misconceptions. Tune in to hear Dr. Harish K. Gagneja share practical, patient-centered strategies to improve screening rates through education, choice, and reducing obstacles to care. Dr. Gagneja is a board-certified gastroenterologist in Austin, Texas.

Guest: Mallik Greene, PhD Real-world data from a recent study show strong adherence to OB/GYN-ordered colorectal cancer (CRC) screening, including both stool DNA testing and follow-up colonoscopy. Tune in to hear Dr. Mallik Greene, an author of the study, discuss its key findings, demographic disparities, and implications for expanding screening in clinical practice. Dr. Greene's background includes a PhD and a Postdoctoral Fellowship in Health Economics and Outcomes Research as well as a Doctorate in Business Administration.

Guest: Mallik Greene, PhD Colorectal cancer screening (CRC) rates remain below national targets, particularly among younger eligible women and underserved populations. Join Dr. Mallik Greene as he discusses the role that OB/GYNs can play in expanding access to screening and improving follow-through in clinical practice. Dr. Greene’s background includes a PhD and a Postdoctoral Fellowship in Health Economics and Outcomes Research as well as a Doctorate in Business Administration.

Host: Brian P. McDonough, MD, FAAFP Guest: Renee Williams, MD, GI New evidence from a report published in Gastroenterology demonstrates that higher adenoma detection rates (ADR) are directly associated with improved colorectal cancer detection, reinforcing ADR as a critical quality metric. Learn more about this study and its implications for optimizing screening quality and reducing missed cancers with Dr. Brian McDonough and Dr. Renee Williams, Professor of Medicine and Associate Chair for Health Equity at the NYU Grossman School of Medicine.

Guest: Darilyn Moyer, MD, MACP, FRCP, FIDSA, FAMWA, FEFIM How do lived experience, community dynamics, and socioeconomic realities shape infectious disease risk and patient decision making? Dr. Darilyn Moyer, Executive Vice President and Chief Executive Officer of the American College of Physicians, explains how incorporating patient context into communication and care strategies can help us better address infectious disease threats like COVID-19.

Presenter: Marcus Shaker, MD, MSc, FAAP, FACAAI, FAAAAI Financial and space limitations are two of the most pressing issues facing allergists and immunologists in academic practice. Fortunately, negotiation principles, like BATNA and ZOPA, and disruptive innovation tactics can help address these common issues. To learn more, we recently spoke with Dr. Marcus Shaker. Not only is he a Professor of Pediatrics and Medicine at the Dartmouth Geisel School of Medicine in New Hampshire, but he also spoke about this topic at the 2026 American Academy of Allergy, Asthma, & Immunology Annual Meeting.

Presenter: Mustafa Ozcam, PhD Emerging research is redefining the role of the gut microbiome in food allergy and immune tolerance. Here to share some of the most groundbreaking findings is Dr. Mustafa Ozcam. He discusses how gut microbes metabolize allergenic proteins, shape immune development, and serve as potential biomarkers to predict oral immunotherapy success in food allergy patients. Dr. Ozcam is an Assistant Professor of Microbiology and Immunology at the University of Maryland School of Medicine, and he spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Presenter: Scott Sicherer, MD Based on a randomized study, children with higher baseline thresholds of peanut reactivity achieved markedly higher rates of sustained unresponsiveness after oral immunotherapy compared with untreated peers. Learn more about this study and its clinical implications with Dr. Scott H. Sicherer. Not only is he a Professor of Pediatrics and the Director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, but he also spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Presenter: Sally E. Wenzel, MD, ATSF Given that severe asthma management is entering a new era of biologically driven precision, Dr. Sally Wenzel joins us to discuss the complexity within Type 2 inflammation and the limitations of relying on a single biomarker assessment. She also differentiates childhood-onset allergic asthma from adult-onset disease, underscoring how age of onset—along with underlying biology—can inform therapeutic strategy. Dr. Wenzel serves as the Director of the Asthma Institute at UPMC, and she spoke about this topic at the 2026 American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Guest: Courtney Crawford, MD, FACS Guest: Raj Maturi, MD While anti-VEGF therapy can deliver vision gains with consistent, frequent injections in clinical trials, it may be challenging to sustain this in real-world practice.1 Ocular gene therapy could be a potential option for patients with neovascular age-related macular degeneration if approved. With this approach, transgenes are delivered to the eye by adeno-associated viruses (AAVs).2-4 Learn more with Drs. Courtney Crawford and Raj Maturi, who shared their perspectives on investigational gene therapy, patient conversations, and surgical considerations at the 2025 American Academy of Ophthalmology annual meeting in Orlando, Florida. Dr. Crawford is a board-certified retina specialist and founder of Star Retina in Burleson, Texas. He previously served for 10 years as a physician in the U.S. Army, where he attained the rank of Lieutenant Colonel. Dr. Maturi is a board-certified retina specialist at the Midwest Eye Institute and founder of Retina Partners Midwest in Carmel, Indiana, where he focuses on macular, retina, and vitreous care. References: Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing visual outcomes in patients with neovascular age-related macular degeneration: the potential value of sustained anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2023;54:654–659. Petrich J, Marchese D, Jenkins C, Storey M, Blind J. …